English Alias: |
N2-trityl olmesartan medoxomil;(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate;Trityl Olmesartan Medoxomil;KKYFOXOGKNDKRS-UHFFFAOYSA-N;Olmesartan Medoxomil EP Impurity D;(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate;UNII-KIU4Z454AM;UNII-KIU4Z454AM;1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;KIU4Z454AM;KIU4Z454AM;N-2 Trityl Olmesartan Medoxomil;N-2 Trityl Olmesartan Medoxomil;OLMESARTAN MEDOXOMIL IMPURITY D [EP IMPURITY];OLMESARTAN MEDOXOMIL IMPURITY D [EP IMPURITY];Olmesartan medoxomil impurity D [EP];Olmesartan medoxomil impurity D [EP];SCHEMBL94332;SCHEMBL94332;1020157-01-0;1020157-01-0;Q27282272;Q27282272;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-((2-triphenylmethyl)-2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-((2-triphenylmethyl)-2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate;N2-Trityl olmesartan medoxomil;N2-Trityl olmesartan medoxomil;N2-Tritylolmesartan medoxomil;N2-Tritylolmesartan medoxomil;N2-Trityl OlMesartan MedoxoMil;N2-Trityl OlMesartan MedoxoMil |